Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAR443579 infusion study in relapsed or refractory AML, MDS, B-ALL, and BPDCN
NL-OMON58721Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jul 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of SAR443579, sponsored by Sanofi. Started Jul 2022; status: completed.
02
Drugs
SAR443579
Beyond the preview
Go deeper on NL-OMON58721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58721.